GRIDS2026: Advancing Therapeutic Development and Clinical Trials in Lysosomal and Rare Disorders

Program: GRIDS2026 will provide a multidisciplinary, case-based program on trial design, endpoint selection, biomarker interpretation, safety monitoring, and post-trial implementation. with focused content on Gaucher disease, Fabry disease, Pompe disease, MPS and ASMD.

GRIDS convenes global experts to address recent advances and challenges in lysosomal storage disorders and rare genetic diseases, fostering collaboration that drives innovation and improves patient outcomes.